| __timestamp | Perrigo Company plc | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 675200000 | 10811000 |
| Thursday, January 1, 2015 | 771800000 | 33001000 |
| Friday, January 1, 2016 | 1205500000 | 64936000 |
| Sunday, January 1, 2017 | 1146500000 | 99909000 |
| Monday, January 1, 2018 | 1125800000 | 127724000 |
| Tuesday, January 1, 2019 | 1166100000 | 161524000 |
| Wednesday, January 1, 2020 | 1175500000 | 182933000 |
| Friday, January 1, 2021 | 1111400000 | 219982000 |
| Saturday, January 1, 2022 | 1210100000 | 278139000 |
| Sunday, January 1, 2023 | 1274600000 | 309799000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Perrigo Company plc from 2014 to 2023.
Perrigo Company plc, a leader in over-the-counter healthcare products, has consistently maintained higher SG&A expenses compared to Ultragenyx, a biopharmaceutical company focused on rare diseases. Over the past decade, Perrigo's SG&A expenses have grown by approximately 89%, peaking in 2023. In contrast, Ultragenyx has seen a staggering increase of over 2,700% in the same period, reflecting its aggressive expansion and investment in niche markets.
This financial trajectory highlights the contrasting business models: Perrigo's steady growth versus Ultragenyx's rapid scaling. Investors and industry analysts should consider these trends when evaluating the strategic directions of these companies.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and Perrigo Company plc
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Perrigo Company plc vs Xenon Pharmaceuticals Inc.
Perrigo Company plc or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Vericel Corporation
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Mesoblast Limited
Perrigo Company plc or MiMedx Group, Inc.: Who Manages SG&A Costs Better?